Literature DB >> 19281192

Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis.

Guido Cavaletti1, Arianna Cassetti, Annalisa Canta, Stefania Galbiati, Alessandra Gilardini, Norberto Oggioni, Virginia Rodriguez-Menendez, Anna Fasano, Grazia Maria Liuzzi, Ursula Fattler, Stefan Ries, John Nieland, Paolo Riccio, Heinrich Haas.   

Abstract

The binding selectivity of charged liposomes to the spinal cord of rats affected by experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, was investigated. Positively and negatively charged liposomes were injected into the tail vein of rats, and blood/brain barrier (BBB) targeting was determined by confocal microscopy as a function of the temporal evolution of the inflammatory response. Accumulation in spinal cord endoneural vessels was observed for cationic, but not for anionic, liposomes, and only in EAE but not in healthy rats. The overall binding efficacy paralleled the severity of the clinical score, but targeting was observed already before clinical manifestation of inflammation. Preferential binding of positively charged liposomes in the course of acute EAE can be ascribed to subtle changes of BBB morphology and charge distribution in a similar way as for the binding of cationic particles to proliferating vasculature in chronic inflammation and angiogenesis. Our findings suggest that vascular changes related to increased binding affinity for cationic particles are very early events within the inflammatory reaction in acute EAE. Investigation of cationic vascular targeting can help to shed further light on these occurrences, and, potentially, new diagnostic and therapeutic options may become available. In neuroinflammatory diseases, cationic colloidal carrier particles may enable intervention at affected BBB by an approach which is independent from permeability increase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19281192     DOI: 10.1021/mp8001478

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

1.  Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated rats.

Authors:  Susanne Herber-Jonat; Rashmi Mittal; Stefan Gsinn; Hermann Bohnenkamp; Eric Guenzi; Andreas Schulze
Journal:  Inflamm Res       Date:  2010-10-12       Impact factor: 4.575

Review 2.  MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS.

Authors:  Eugene D Ponomarev; Tatiana Veremeyko; Howard L Weiner
Journal:  Glia       Date:  2012-05-31       Impact factor: 7.452

Review 3.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

4.  Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats.

Authors:  Mireia Campos-Martorell; Mary Cano-Sarabia; Alba Simats; Mar Hernández-Guillamon; Anna Rosell; Daniel Maspoch; Joan Montaner
Journal:  Int J Nanomedicine       Date:  2016-06-29

Review 5.  Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances.

Authors:  Xiaoqian Niu; Jiejian Chen; Jianqing Gao
Journal:  Asian J Pharm Sci       Date:  2018-10-22       Impact factor: 6.598

Review 6.  Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.

Authors:  Pauline E M van Schaik; Inge S Zuhorn; Wia Baron
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

7.  Liposome-encapsulated peptides protect against experimental allergic encephalitis.

Authors:  Alexey A Belogurov; Alexey V Stepanov; Ivan V Smirnov; Dobroslav Melamed; Andrew Bacon; Azad E Mamedov; Vitali M Boitsov; Lidia P Sashchenko; Natalia A Ponomarenko; Svetlana N Sharanova; Alexey N Boyko; Michael V Dubina; Alain Friboulet; Dmitry D Genkin; Alexander G Gabibov
Journal:  FASEB J       Date:  2012-10-09       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.